- Home
- ALVR
ALVR
AlloVir Inc.
as 07-26-2024 4:00pm EST
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 80.5M | IPO Year: | 2020 |
| Target Price: | $5.88 | AVG Volume (30 days): | 594.2K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.58 - $3.75 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of AlloVir Inc. (ALVR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hagen Brett R | ALVR | Chief Accounting Officer | Jul 2 '24 | Sell | $0.72 | 304 | $218.88 | 75,177 | SEC Form 4 |
| Miller Edward | ALVR | General Counsel | Jul 2 '24 | Sell | $0.72 | 379 | $272.88 | 220,117 | SEC Form 4 |
| Sinha Vikas | ALVR | See Remarks | Jul 2 '24 | Sell | $0.72 | 939 | $676.08 | 1,165,394 | SEC Form 4 |
| Brainard Diana | ALVR | Chief Executive Officer | May 21 '24 | Sell | $0.79 | 5,149 | $4,079.55 | 784,471 | SEC Form 4 |
| Miller Edward | ALVR | General Counsel | May 17 '24 | Sell | $0.75 | 420 | $314.71 | 220,496 | SEC Form 4 |
| Brainard Diana | ALVR | Chief Executive Officer | May 17 '24 | Sell | $0.75 | 3,075 | $2,304.10 | 789,620 | SEC Form 4 |
| Hagen Brett R | ALVR | Chief Accounting Officer | May 17 '24 | Sell | $0.75 | 541 | $405.37 | 75,481 | SEC Form 4 |
| Sinha Vikas | ALVR | See Remarks | May 17 '24 | Sell | $0.75 | 3,143 | $2,355.05 | 1,129,996 | SEC Form 4 |
| Brainard Diana | ALVR | Chief Executive Officer | May 3 '24 | Sell | $0.80 | 10,240 | $8,151.04 | 792,695 | SEC Form 4 |
| Hagen Brett R | ALVR | Chief Accounting Officer | May 3 '24 | Sell | $0.80 | 1,597 | $1,271.21 | 76,022 | SEC Form 4 |
| Sinha Vikas | ALVR | See Remarks | May 3 '24 | Sell | $0.80 | 4,957 | $3,945.77 | 1,133,139 | SEC Form 4 |
| Miller Edward | ALVR | General Counsel | May 3 '24 | Sell | $0.80 | 2,311 | $1,839.56 | 220,916 | SEC Form 4 |
| Hagen Brett R | ALVR | Chief Accounting Officer | Apr 19 '24 | Sell | $0.75 | 480 | $360.00 | 77,619 | SEC Form 4 |
| Hagen Brett R | ALVR | Chief Accounting Officer | Apr 19 '24 | Sell | $0.75 | 473 | $355.03 | 78,099 | SEC Form 4 |
| Brainard Diana | ALVR | Chief Executive Officer | Apr 19 '24 | Sell | $0.75 | 9,601 | $7,206.51 | 802,935 | SEC Form 4 |
| Sinha Vikas | ALVR | See Remarks | Apr 19 '24 | Sell | $0.75 | 1,521 | $1,141.66 | 1,139,953 | SEC Form 4 |
| Sinha Vikas | ALVR | See Remarks | Apr 19 '24 | Sell | $0.75 | 1,857 | $1,392.75 | 1,138,096 | SEC Form 4 |
| Miller Edward | ALVR | General Counsel | Apr 19 '24 | Sell | $0.75 | 626 | $469.88 | 223,984 | SEC Form 4 |
| Miller Edward | ALVR | General Counsel | Apr 19 '24 | Sell | $0.75 | 757 | $567.75 | 223,227 | SEC Form 4 |
| Hagen Brett R | ALVR | Chief Accounting Officer | Apr 2 '24 | Sell | $0.77 | 281 | $216.93 | 78,572 | SEC Form 4 |
| Miller Edward | ALVR | General Counsel | Apr 2 '24 | Sell | $0.77 | 368 | $284.10 | 224,610 | SEC Form 4 |
| Sinha Vikas | ALVR | See Remarks | Apr 2 '24 | Sell | $0.77 | 885 | $683.22 | 1,141,474 | SEC Form 4 |
| Hagen Brett R | ALVR | Chief Accounting Officer | Feb 20 '24 | Sell | $0.70 | 494 | $343.43 | 78,853 | SEC Form 4 |
| Brainard Diana | ALVR | Chief Executive Officer | Feb 20 '24 | Sell | $0.70 | 3,097 | $2,153.03 | 819,224 | SEC Form 4 |
| Brainard Diana | ALVR | Chief Executive Officer | Feb 20 '24 | Sell | $0.71 | 5,155 | $3,650.26 | 814,069 | SEC Form 4 |
Latest AlloVir Inc. News
ALVR Breaking Stock News: Dive into ALVR Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*
PR Newswire
2 months ago
NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities
Business Wire
2 months ago
Form 8.3 - International Distribution Services plc
Business Wire
2 months ago
Form 8.3 - Darktrace plc
Reuters
2 months ago
US Supreme Court rejects Kroger challenge to Grubhub trademark win
Investor's Business Daily
2 months ago
Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect
GlobeNewswire
2 months ago
Middlefield Canadian Income PCC: Net Asset Value(s)
Business Wire
2 months ago
GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina
Compare ALVR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALVR AlloVir Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.